Amphastar (AMPH) Form 144: Proposed Sale of 500 Shares via UBS on NASDAQ
Rhea-AI Filing Summary
Form 144 notice by Floyd Peterson for Amphastar Pharmaceuticals, Inc. (AMPH). The filer notifies a proposed sale of 500 shares of common stock through UBS Financial Services on NASDAQ with an approximate sale date of 09/02/2025 and an aggregate market value listed at $15,450.00. The shares were acquired as RSUs on 06/07/2022. The filing also discloses three sales by the same person in the past three months totaling 1,500 shares on 06/02/2025, 07/02/2025 and 08/01/2025 with combined gross proceeds of $34,984.75. The form includes the required representation that the seller is not aware of undisclosed material adverse information.
Positive
- Disclosure compliance: Proposed sale and recent transactions are reported on Form 144 using a registered broker (UBS).
- Traceable acquisition: Shares were acquired as RSUs on 06/07/2022, and acquisition details are provided.
Negative
- Insider selling activity: The filer sold 1,500 shares in the past three months and proposes to sell another 500 shares, which may be viewed negatively by some investors.
- Missing context: The filing does not state the filer’s relationship to the issuer or provide a 10b5-1 plan adoption date.
Insights
TL;DR: Modest insider sales disclosed; proposed sale is small relative to total outstanding shares.
The filing shows a planned sale of 500 shares and prior sales totaling 1,500 shares. With 46,495,077 shares outstanding the transactions are immaterial to company capitalization. Disclosure via Form 144 and use of a registered broker (UBS) indicate compliance with Rule 144 procedures. No purchase plan date or relationship to the issuer is provided in the filing text, and there is no financial performance data in this notice to assess motivation.
TL;DR: Filing meets procedural requirements but lacks certain contextual details about relationship to issuer.
The document supplies acquisition details (RSU grant date 06/07/2022), broker information, and past sale records, supporting traceability for transfer compliance. The signer affirms absence of undisclosed material adverse information, which is standard. The filing does not state the filer’s relationship to the issuer or any 10b5-1 plan adoption date, limiting assessment of planned trading safeguards.